Grail’s Galleri Trial Missed Its Primary Endpoint: What BD Teams and Investors Need to Know

Grail Galleri Misses Primary Endpoint: Impact for Pharma BD

Grail’s NHS-Galleri trial did not show a statistically significant reduction in late-stage cancers. However, a substantial reduction in stage 4 cancers and a shift to stage 3 diagnoses reveal a more nuanced picture for investors and BD teams. As pharma professionals conduct Galleri cancer test reviews, the mixed data and a separate clinical hold demand a careful reassessment of multi-cancer early detection (MCED) partnerships.

Key Takeaways

• Grail’s NHS-Galleri trial failed its primary endpoint: no statistically significant reduction in late-stage cancer diagnoses. A shift from stage 4 to stage 3 cancers was seen, but overall late-stage count did not improve.
• Separately, a prospective Galleri trial was temporarily placed on hold, likely due to poor clinical performance.
• For BD teams and investors, the data is mixed: the test may shift stage at diagnosis but has not yet proven a mortality benefit, and sensitivity limitations were highlighted by 196 false negatives in the NHS-Galleri trial.

What Did the NHS-Galleri Trial Show?

On June 4, 2026, STAT reported that Grail’s multi-cancer early detection test (MCED), Galleri, did not achieve its primary endpoint in the NHS-Galleri trial. The study enrolled over 140,000 participants in the UK. The Galleri test detected a substantial reduction in stage 4 cancers, but this was offset by a substantial increase in stage 3 cancers. The net reduction in late-stage (stage 3 and 4) diagnoses was not statistically significant. The trial also recorded 196 false negatives—participants who received a negative Galleri result but were diagnosed with cancer within 12 months. This sensitivity limitation is a key concern for any MCED test aiming for broad deployment.

The NHS-Galleri trial was designed to evaluate whether screening with Galleri could reduce the incidence of late-stage cancers. While the stage-shift signal is intriguing—fewer stage 4 cancers are a positive outcome—the increase in stage 3 cancers suggests the test may detect cancers at an earlier point within late-stage, but not early enough to change overall late-stage counts. For pharma BD teams evaluating MCED platforms, this distinction matters: a stage shift without a clear reduction in late-stage incidence makes it harder to convince payers and regulators of clinical utility.

How Should Pharma BD Teams Adjust Their MCED Strategy?

The negative primary endpoint and the clinical hold on a separate prospective trial force BD teams to recalibrate their expectations for MCED. When conducting Galleri cancer test reviews, teams should now focus on the following criteria:

• Prospective data with hard endpoints: Any MCED partner should have trials powered for mortality or late-stage incidence reduction, not just stage shift.
• Sensitivity across cancer types: The 196 false negatives in the NHS-Galleri trial underscore that Galleri misses cancers at a rate that may limit its cost-effectiveness. Compare this to single-cancer screening tests such as low-dose CT for lung cancer, which have clearer sensitivity benchmarks.
• Regulatory alignment: The FDA’s framework for cancer screening tests demands well-controlled studies with definitive endpoints. BD teams should prioritise partners who have engaged the FDA on study design before launching large trials.

The clinical hold on a Galleri trial—reported in a PMC analysis as likely due to poor performance—adds reputational risk. Investors should monitor whether Grail can resolve the hold quickly or whether it will need to run additional studies. Competitors such as Exact Sciences and Guardant Health may see an opening to differentiate their own MCED or multi-cancer detection platforms if they can demonstrate stronger sensitivity and a statistically significant reduction in late-stage cancer.

Frequently Asked Questions

Related coverage

• Daraxonrasib Pancreatic Cancer: What RevMed’s Breakthrough Means for Patients and Pharma
• FDA Approves Companion Diagnostic for Inavolisib in HR+/HER2–, PIK3CA-Mutated Breast Cancer
• Revolution Medicine Pancreatic Cancer: Demand Surge Strains Daraxonrasib Access